Cagrisema 12 Pen - BodyPharm
Description
CagriSema is a next-generation injectable weight-management medication being developed. It combines two different appetite-regulating medicines:
-
Cagrilintide – a long-acting amylin analogue.
-
Semaglutide – a GLP-1 receptor agonist, the active ingredient in Ozempic and Wegovy.
The idea is to target two complementary appetite pathways rather than relying on GLP-1 activity alone.
How does it work?
Cagrilintide — the amylin pathway
Mimics amylin, a hormone naturally released alongside insulin after eating. It helps regulate appetite, increase fullness and reduce food intake.
Semaglutide — the GLP-1 pathway
Activates GLP-1 receptors, helping regulate appetite, slow gastric emptying and improve glucose-dependent insulin secretion.
Together: The combination is designed to increase satiety, reduce hunger and help people consume fewer calories.
How effective is it?
The clinical results have been impressive.
In the Phase 3 REDEFINE 1 trial, CagriSema achieved approximately 22.7% average weight loss over 68 weeks under the trial's efficacy estimand. Results were lower when accounting for treatment discontinuation and other real-world factors.
An important comparison:
|
Medication |
Main mechanism |
|---|---|
|
Semaglutide |
GLP-1 |
|
Tirzepatide |
GIP + GLP-1 |
|
CagriSema |
Amylin + GLP-1 |
Interestingly, in the 2026 REDEFINE 4 head-to-head trial, CagriSema achieved 23% weight loss over 84 weeks but did not meet its primary endpoint of demonstrating non-inferiority to tirzepatide 15 mg.
Is it approved yet?
As of 9 November 2026:
-
Submitted its US FDA application in December 2025.
-
An FDA decision is expected in Q4 2026.
-
It remains an investigational treatment rather than an established, generally approved weight-loss product.
What about side effects?
Because it includes semaglutide and an amylin analogue, gastrointestinal side effects are important considerations:
-
Nausea
-
Vomiting
-
Constipation
-
Diarrhoea
-
Abdominal discomfort
-
Reduced appetite
There are also concerns around dehydration, gallbladder complications and maintaining adequate nutrition during substantial weight loss.
It should not simply be added to an existing semaglutide or tirzepatide regimen.
Why is it interesting?
I think the most interesting aspect of CagriSema is its dual-hormone approach. Rather than simply increasing GLP-1 activity, it adds an entirely different appetite-regulating pathway.
For the LIFE.OS research side, it is worth understanding as part of the next generation of metabolic therapies, alongside tirzepatide and emerging amylin-based treatments.
One distinction worth exploring: CagriSema is not the same as combining cagrilintide and semaglutide independently. The clinical product is a specifically developed fixed-dose combination with its own formulation, dosing and clinical-trial evidence. I would be cautious about research-vial combinations being marketed as equivalent.
Shipping
We ship all orders using a well-known national courier company to ensure reliable delivery and shipment tracking. Due to the nature of peptide products, careful packaging and timely delivery are prioritised.
Shipping Timeframes
Orders are typically delivered within 3–5 business days from the date of dispatch
Delivery times may vary depending on location, courier capacity, and external factors beyond our control
Business days exclude weekends and public holidays
Dispatch timelines will be communicated at checkout or in your order confirmation.
Shipping Rates
Standard shipping rates apply
We use a flat-rate shipping fee for all orders, regardless of order size or value
Shipping rates are subject to change without prior notice
The applicable shipping fee will always be displayed at checkout before payment is completed.
Disclaimer
The information provided on this website is intended for educational and informational purposes only. Content related to peptides, supplements, biohacking protocols, or health optimization is not intended as, and should not be considered, medical advice, nor does it replace consultation with a qualified healthcare professional.
Some peptides and compounds discussed on this website may be in the research or investigational stage, may not be approved by regulatory authorities, and may not be intended for human use. References to such compounds are provided solely for general scientific discussion and informational purposes.
Nothing on this website should be interpreted as a diagnosis, treatment, cure, or prevention of any disease or medical condition. Individual health needs vary, and decisions regarding health, supplementation, or medical care should always be made in consultation with a licensed medical practitioner.
By using this website, you acknowledge and agree that you assume full responsibility for how you interpret and use the information provided, and that the website, its owners, operators, and contributors are not liable for any outcomes resulting from reliance on the content.